Rallybio Corp Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rallybio Corp (RLYB) on August 2, 2022, reporting events occurring on August 1, 2022. The company is a Delaware corporation incorporated as an emerging growth company, with principal executive offices in New Haven, Connecticut.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size from nine to ten directors.
- New Appointment: Wendy K. Chung, M.D., Ph.D., was appointed as a Class III director effective August 1, 2022.
- Committee Assignment: Dr. Chung was appointed to the Nominating and Corporate Governance Committee.
- Term Details: Dr. Chung's term will expire at the 2024 annual meeting of shareholders.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. Dr. Chung's compensation will follow the existing non-employee director compensation policy detailed in the April 25, 2022, Definitive Proxy Statement. No material interests or undisclosed arrangements were reported in connection with the appointment.
Key Facts for Investor Verification
- Verify Dr. Chung's professional background and qualifications as a new Class III director.
- Review the April 25, 2022, Definitive Proxy Statement for details on the non-employee director compensation policy applicable to Dr. Chung.
- Confirm the effective date of the board expansion (August 1, 2022) and the expiration of the new director's term (2024 annual meeting).
- Note that this filing does not impact the company's financial statements or liquidity position.